Hepatitis C Clinical Trial
Official title:
Comparison of FibroScan With Histological Evaluations of Liver Fibrosis in Patients With Hepatitis B and C Presenting for Liver Biopsy
This study will examine the effectiveness of the FibroScan device in differentiating fibrosis in patients with hepatitis B and C. The FibroScan measures liver stiffness and will be correlated to the liver biopsy to see if it can diagnose the stage of liver disease. Patients who are scheduled to have a liver biopsy will also have a fibroscan and the stiffness will be correlated with the biopsy stage.
STUDY OBJECTIVES:
Co -Primary Aims:
- Diagnosis of cirrhosis in patients with chronic viral hepatitis B and C;
- Correlation of the FibroScan measurement with Metavir liver fibrosis scores by
differentiating no/mild fibrosis (F0-F1) from severe fibrosis (F2-F4).
STUDY DESIGN:
This is a multi-center study in which the FibroScan measurements will be collected
prospectively from patients with chronic hepatitis B and C virus presenting for liver biopsy.
The study duration will be 12 months. The study will initially have 3 investigational sites
in the United States. Up to 3 more investigational sites may be identified to participate in
the trial.
Study Sites:
Initially the following three sites will participate in the trial:
Duke University Medical Center, Durham, NC: Keyur Patel, M.D.; Beth Israel Deaconess Medical
Center and Harvard Medical School, Boston, MA: Nezam H. Afdhal, M.D.; St. Louis University,
St. Louis, MO: Bruce R. Bacon M.D.
Study Population:
Subjects with chronic liver diseases secondary to chronic hepatitis C and hepatitis B,
undergoing a liver biopsy as the standard of care for their disease, will be eligible for the
study. Subjects with hepatitis C, co-infected with other infectious viral diseases, such as
hepatitis B or HIV-1, or both, may also be candidates for study enrollment provided the
inclusion/exclusion criteria are met.
The subjects must be scheduled for liver biopsy either prior to treatment (treatment naïve)
or, if previously treated, they must have been off treatment for at least three (3) months.
The time between the date of the FibroScan reading and the date of biopsy must not exceed six
(6) months.
Sample Size:
A total of at least 300 evaluable patients (males and females) will be enrolled in this
study. Enrollment will be considered competitive with no site enrolling more than 50% of the
study population. Sample size is based on a prevalence of 20% cirrhosis.
Subject Inclusion Criteria:
- Subject is able to give informed consent for this study and agrees to provide a blood
sample.
- Subject must be at least 18 years of age.
- Subject has had or will have a liver biopsy for chronic liver disease, secondary to HBV
or HCV or within 6 months of FibroScan (experimental cohort 1 only).
- Subjects who have hepatitis C (HCV) or hepatitis B (HBV) should be treatment naïve or
off interferon therapy or nucleoside/nucleotide analogs for HBV for a minimum of 3
months prior to the FibroScan and liver biopsy.
Subject Exclusion Criteria:
- Unable or unwilling to provide informed consent.
- Confirmed diagnosis and/or history of malignancy, or other terminal disease.
- Uninterpretable biopsy specimen.
- Missing critical clinical, biochemical and/or demographic information.
- Receiving anti-viral therapy for infection of HCV or HBV within 3 months prior to the
FibroScan and liver biopsy.
- Subject with other chronic liver disease, including Wilson's disease, alpha
1-antitrypsin deficiency, cholestatic liver disease, or hemochromatosis.
- Patient with clinical ascites
- Patients with morbid obesity defined as a body mass index (BMI) of greater than or equal
to 40.
- Patients who are pregnant
- Patients who have an implantable cardiac device such as defibrillator or pacemaker
SAMPLE REQUIREMENTS and TESTING:
A minimum of 8 valid measurements will be obtained for each subject from the right lobe of
the liver. The tip of the probe transducer will be covered with coupling gel and placed on
the skin, between the ribs at the level of the right lobe of the liver. The operator,
assisted by an ultrasonic time motion image, will locate a portion of the liver that is at
least 4cm thick and free of large vascular structures. The depth of measurement will be
between 25 mm and 65 mm. During the acquisition subjects will lie on their back with the
right arm behind the head, in a similar position to that used for liver biopsy. The physician
will take the measurements with the probe placed in the intercostal space. The median value
of the estimates will be kept as the elasticity value of the liver for a given patient. The
entire examination should last approximately 5 minutes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Recruiting |
NCT04510246 -
Link Hepatitis C Notifications to Treatment in Tasmania
|
N/A | |
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
Completed |
NCT03109457 -
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
|
||
Completed |
NCT01458054 -
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
|
Phase 1 | |
Completed |
NCT03740230 -
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
|
||
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Completed |
NCT00006301 -
Immune Response to Hepatitis C Virus
|
||
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Recruiting |
NCT04405024 -
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
|
N/A | |
Completed |
NCT04525690 -
Improving Inpatient Screening for Hepatitis C
|
N/A | |
Completed |
NCT04033887 -
Evaluation Study of RDTs Detecting Antibodies Against HCV
|
||
Withdrawn |
NCT04546802 -
HepATocellular Cancer Hcv Therapy Study
|
Phase 3 | |
Active, not recruiting |
NCT02961426 -
Strategic Transformation of the Market of HCV Treatments
|
Phase 2/Phase 3 | |
Completed |
NCT02869776 -
Integrating HCV and HIV Screening During the Era of HIV Antigen Testing
|
N/A | |
Completed |
NCT03186313 -
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
|
Phase 3 | |
Completed |
NCT02992184 -
PoC-HCV Genedrive Viral Detection Assay Validation Study
|
N/A |